Обзорная статья

Parkinson’s Disease in Central Asian and Transcaucasian Countries: A Review of Epidemiology, Genetics, Clinical Characteristics, and Access to Care

Rauan KaiyrzhanovUniversity College London, Institute of Neurology, Department of Neuromuscular Disorders, Queen Square, WC1N 3BG London, UKMie RizigUniversity College London, Institute of Neurology, Department of Neuromuscular Disorders, Queen Square, WC1N 3BG London, UKAkbota AitkulovaAl-Farabi Kazakh National University, Department of Biology and Biotechnology, 71 Al-Farabi Ave., 050040 Almaty, KazakhstanNazira ZharkinbekovaSouth Kazakhstan Medical Academy, Department of Neurology, 1/1 Al-Farabi Avenue, 160019 Shymkent, KazakhstanChingiz ShashkinKazakh National Medical University, Department of Neurology, 94 Tole Bi Street, 050000 Almaty, KazakhstanGulnaz KaishibayevaAltynay KarimovaХайбуллин Т.Н.Semey Medical University, Department of Neurology and Neurophysiology, 103 Abai Street, 071400 Semey, KazakhstanDinara SadykovaAstana Medical University, 49A Beibitshilik Street, 01000 Nur-Sultan, KazakhstanManizha GanievaAvicenna Tajik State Medical University, Department of Neurology and Medical Genetics, 139 Rudaki Street, 734001 Dushanbe, TajikistanKh. A. RasulovaTashkent Pediatric Medical Institute, Department of Internal Diseases and Research Laboratory, 223 Bogishamol Street, 100140 Tashkent, UzbekistanHenry HouldenUniversity College London, Institute of Neurology, Department of Neuromuscular Disorders, Queen Square, WC1N 3BG London, UK

Parkinson s Diseasejournal2019en

ABI

Аннотация

Our understanding of Parkinson's disease (PD) has significantly accelerated over the last few years, but predominant advances have been made in developed, Western countries. Little is known about PD in the Central Asian (CA) and Transcaucasian (TC) countries. Here, we review the clinical characteristics, treatments used, epidemiology, and genetics of PD in CA and TC countries via a methodological search in MEDLINE, EMBASE, Scopus, Web of Science, and Google Scholar databases. For the acquisition of PD care-related data, the search was extended to the local web resources. Our findings showed that PD prevalence in the region is averaging 62 per 100,000 population. The mean age of onset is 56.4 ± 2.8 in females and 63.3 ± 3.5 in males. Large-scale national studies on PD prevalence from the region are currently lacking. A limited number of genetic studies with small cohorts and inconclusive results were identified. The G2019S LRRK2 mutation, the commonest mutation in PD worldwide, was found in 5.7% of patients with idiopathic PD and 17.6% of familial cases in 153 Uzbek patients. Our review highlighted systematic deficiencies in PD health care in the region including lacks of neurologists specializing in PD, delays in PD diagnosis, absence of specialized PD nurses and PD rehab services, limited access to PD medications and surgery, and the unavailability of PD infusion therapies. Overall, this article demonstrated the paucity of data on this common neurological disorder in CA and TC countries and identified a number of healthcare areas that require an urgent consideration. We conclude that well-designed large-scale epidemiological, genetic, and clinical studies are desperately needed in this region. Healthcare professionals, local and national institutions, and stakeholders must come together to address deficiencies in PD healthcare systems in CA and TC countries.

Перевод пока недоступен

Темы

Parkinson's Disease Mechanisms and Treatments Neurological disorders and treatments Nuclear Receptors and Signaling

Идентификаторы

DOI: 10.1155/2019/2905739

Цитирования и источники

Цитирований: 0Использованных источников: 11

Показатели — AkademScholar